Results 141 to 150 of about 35,808 (310)

Defensive medicine in dermatological practice – Dermatopathology as a mirror of structural challenges

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Defensive medicine refers to diagnostic or therapeutic actions taken primarily to reduce legal liability rather than to benefit the patient. In dermatopathology, defensive practices manifest in frequent immunohistochemical testing, overly cautious report phrasing, and reliance on multidisciplinary tumor boards.
Cornelia Sigrid Lissi Müller, Torsten Hansen, Claus Renzelmann   +2 more
wiley   +1 more source

The Histological Spectrum of Early Mycosis Fungoides: A Study of 58 Saudi Arab patients

Oman Medical Journal, 2012
Objectives: The histopathological diagnosis of Mycosis Fungoides (MF) is challenging in its early stages and can easily be confused with inflammatory dermatoses.
Ammar Al Rikabi, Hala Kassouf Kfoury, Shaesta Naseem Zaidi, Maha Arafah, Khalid Al Ghamdi   +4 more
doaj  

"Peeling paint" dermatosis in a leukemia patient. [PDF]

, 2020
Jerkins, James, Juhasz, Margit, Laquer, Vivian, Smith, Janellen   +3 more
core  

Validation of the German version of Infants and Toddlers Dermatology Quality of Life (InToDermQoL) Questionnaire

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Skin diseases can greatly impair quality of life (QoL) of pediatric patients and their families. The Infants and Toddlers Dermatology Quality of Life questionnaire (InToDermQoL) is the first skin‐generic instrument assessing QoL in children ≤ 4 years, as reported by their caregiver. This study aimed to psychometrically
Juliane Traxler, Neuza da Silva Burger, Matthias Augustin, Hagen Ott, Sanna Hoffmann, Regina Fölster‐Holst, Maria Baumeister, Petra Staubach, Rachel Sommer   +8 more
wiley   +1 more source

A review of skin microbiome and new challenges to cosmetic microbiome‐friendly formulations

International Journal of Cosmetic Science, EarlyView.
Microbiome‐friendly concepts offer new perspectives for a healthy relationship between cosmetic use and the skin microbiome, especially the interaction of non‐biotic cosmetic ingredients with the skin, requiring further studies to clarify the dynamics between the skin microbiome and different classes of cosmetic ingredients.
Yasmin Rosa Santos, Newton Andréo‐Filho, Patricia Santos Lopes, Vânia Rodrigues Leite‐Silva   +3 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Clinico-Epidemiological Study of Facial Dermatoses. [PDF]

Cureus
Tiwari M, Tripathi M, Tiwari A, Thagele P, Choudhary N, Rana N.   +5 more
europepmc   +1 more source

Response to Choi et al, "Pathergy beyond neutrophilic dermatoses: A case of localized leukemia cutis at the site of intravenous infiltration". [PDF]

JAAD Case Rep
Hayek SJ, Nguyen CN, Kivelevitch D.
europepmc   +1 more source

The neglected majority: Inverse relationship between prevalence and global research activity of 15 dermatological diseases

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Oliver Brandt, Erere Otrofanowei, Ncoza Dlova, Simon M. Mueller   +3 more
wiley   +1 more source

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Data from 2731 patients with hidradenitis suppurativa (HS) treated with biologics for 12–16 weeks in phase III randomized controlled trials (RCT) were included in a network meta‐analysis (NMA). Adalimumab showed the highest efficacy in achieving a clinical HS response 50 (HiSCR50) and the lowest incidence of adverse events (AE).
Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, Lars E. French, Benjamin Kendziora   +4 more
wiley   +1 more source